Active • Host: HEK293 cells • AA: 21-431 • Tag: C-terminal His • MW: 47.8 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

uPA (human, recombinant)

Item No. 44195

Product Insert (PDF)
Technical Information
Synonyms
  • PLAU
  • U-Plasminogen Activator
Purity
≥97% estimated by SDS-PAGE
Endotoxin Testing
<1.0 EU/μg of the protein as determined by the LAL method
Source
Active recombinant human C-terminal His-tagged uPA expressed in HEK293 cells
Amino Acids
21-431
MW
47.8 kDa
Formulation (Request formulation change)
Lyophilized from sterile 25 mM HEPES, 150 mM sodium chloride, 10 mM calcium chloride, pH 5.3, 5% trehalose, 5% mannitol, and 0.01% Tween-80
UniProt Accession №
P00749
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    50 µg

    $348

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Urokinase-type plasminogen activator (uPA) is a serine protease that converts enzymatically inactive plasminogen into active plasmin.1,2 It is synthesized and released as a single polypeptide chain called pro-uPA, which contains three domains: a growth factor domain (GFD), a kringle domain, and a serine protease domain.2 The secreted polypeptide is cleaved by a variety of proteases, including cathepsin B, cathepsin L, trypsin, and plasmin, to form two-chain uPA. Two-chain uPA is further cleaved into two fragments: low molecular weight uPA containing the serine protease domain and a catalytically inactive amino-terminal fragment containing the GFD and kringle domain. Expression of PLAU, the gene encoding uPA, is increased several fold in tumor cells over non-tumor cells.1,2 Increased serum uPA levels are associated with an increased number of tumor metastases in patients with metastatic breast cancer.3 Cayman’s uPA (human, recombinant) protein can be used for enzyme activity assay and Western blot (WB) applications. This protein consists of 422 amino acids, has a calculated molecular weight of 47.8 kDa, and a predicted N-terminus of Ser21 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is 51 kDa, 35.4 kDa, and 19.1 kDa, corresponding to unprocessed pro-uPA, the inactive amino-terminal fragment, and low molecular weight uPA, respectively, due to glycosylation and cleavage. This purified protein was activated by trypsin in vitro.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Schmitt, M., Wilhelm, O., Jänicke, F., et al. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): A new target in tumor invasion and metastasis. J. Obstet. Gynaecol. (Toyko 1995) 21(2), 151-165 (1995).

    2. Mahmood, N., Mihalcioiu, C., and Rabbani, S.A. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications. Front. Oncol. 8, 24 (2018).

    3. Banys-Paluchowski, M., Witzel, I., Aktas, B., et al. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. Sci. Rep. 9(1), 2318 (2019).